Search results

  1. M

    Treating patients suffering from myalgic encephalopathy/chronic fatigue syndrome (ME/CFS) with sodium dichloroacetate, Comhaire 2018

    The trial will be initiated as soon as, and provided that the DCA is officially accepted and registered as a food supplement.
  2. M

    Treating patients suffering from myalgic encephalopathy/chronic fatigue syndrome (ME/CFS) with sodium dichloroacetate, Comhaire 2018

    It is strange indeed. The formula generated by the logistic regression analysis with stepwise elimination also includes the total score of the FSS. It is an observation, not an explanation. I try to inform those among you who are interested in the evolution of my research. I hope you appreciate...
  3. M

    Treating patients suffering from myalgic encephalopathy/chronic fatigue syndrome (ME/CFS) with sodium dichloroacetate, Comhaire 2018

    THis comment is perfectly correct. The vertical axis shows (p) not logit (p). Thank you!
  4. M

    Treating patients suffering from myalgic encephalopathy/chronic fatigue syndrome (ME/CFS) with sodium dichloroacetate, Comhaire 2018

    What I found is that the calculated formula alows for rather clear differentiation between reponders and non-responders. The (p) in the "logit(p)" means the probability that a particular person does belong to the group of responders (probability between 0 and 1). It is commonly called the...
  5. M

    Treating patients suffering from myalgic encephalopathy/chronic fatigue syndrome (ME/CFS) with sodium dichloroacetate, Comhaire 2018

    This is a proof of principle, pilot, pragmatic trial. It is what it is, not more or less.
  6. M

    Treating patients suffering from myalgic encephalopathy/chronic fatigue syndrome (ME/CFS) with sodium dichloroacetate, Comhaire 2018

    Your comment is correct. However, it is remarkable that there is apparently such formula that is confirmed each time when new patients are entered. The most important point is that it should be possible to select patients to be enrolled for a double blind trial since it makes little sense to...
  7. M

    Treating patients suffering from myalgic encephalopathy/chronic fatigue syndrome (ME/CFS) with sodium dichloroacetate, Comhaire 2018

    Thank you for your comments and suggestions. I am - indeed - a medical doctor, retired professor of internal medicine, endocrinology (diseases of hormone-producing glands) and metabolism at the University of Gent, Belgium. I have practiced so-called allopathic (classical) medicine for 54 years...
  8. M

    Treating patients suffering from myalgic encephalopathy/chronic fatigue syndrome (ME/CFS) with sodium dichloroacetate, Comhaire 2018

    As the number of patients who are included into the pragmatic trial increases, it becomes evident that it is possible to predict with reasonable confidence who will, and who will not respond favorably to the treatment. For the scientist among you: the area under the ROC curve is 0.90. But...
  9. M

    A Novel Nutriceutical Treatment of ME/CFS, 2017, Comhaire

    Reply this is indeed based on a relatively small number of observations, and is performed a posteriori, by calculating the formula derived from the logistic regression analysis (MedCalc statistical program).
  10. M

    A Novel Nutriceutical Treatment of ME/CFS, 2017, Comhaire

    As argued before, this is an open-label, proof of principle or proof of concept pilot trial performed in real life circumstances and, therefore, it may be called pragmatic. The message that I have transmitted is that a foodsupplement, that inhibits Pyruvatedehydrogenase kinase and that...
  11. M

    A Novel Nutriceutical Treatment of ME/CFS, 2017, Comhaire

    A pilot, open label, proof-of-principle, pragmatic trial is the first step in a sequence of validation. For the patients who benefit from the treatment, the effect is what counts. In my view of medicine (which I practice since 54 years), the feeling of health and happiness of the patients is...
  12. M

    A Novel Nutriceutical Treatment of ME/CFS, 2017, Comhaire

    The dose level is between 5 and 10 mg per kg body weight, generally 400 mg once per day.
  13. M

    A Novel Nutriceutical Treatment of ME/CFS, 2017, Comhaire

    A pragmatic trial is, by definition, not blinded, since it is an open-label, prospective, real life trial. Please look up the definition of "pragmatic trial" via internet.
  14. M

    A Novel Nutriceutical Treatment of ME/CFS, 2017, Comhaire

    The formulation is fully protected during 12 months while the "novelty" is being checked. During that period "provisional protection" completely covers the intellectual property-rights of the inventor. The complementary ingredients of the nutriceutical are: Vitamin B1, alfa-lipoic acid...
  15. M

    A Novel Nutriceutical Treatment of ME/CFS, 2017, Comhaire

    sorry... should read stepwise elimination. ;)
  16. M

    A Novel Nutriceutical Treatment of ME/CFS, 2017, Comhaire

    in a short "proof of principle" pragmatic trial, reported previously, I have referred to a new nutriceututical treatment for ME/CFS. In a larger trial, 45% of patients reacted favourably to this treatment, which contains - among other ingrediënts - sodium dichloroacetate, and that has now been...
Back
Top Bottom